INSIGHTS ON CELL & GENE OUTSOURCING ISSUES

• No Cells, No Limits To DNA Production: Inside Synthetic DNA

  Here, we walk you through our groundbreaking, enzymatic DNA manufacturing process that enables the production of linear DNA templates for IVT mRNA synthesis — without the use of cells.

• Slow The Burn: How To Make Risk-Resilient Vendor Choices

  Learn how to identify common CRO selection pitfalls and apply expert-backed strategies to protect your clinical program from costly risks and delays.

• 3 Key Bottlenecks In Cell Therapy Supply Chains

  Ensure your cell therapy program is prepared for the future by learning how to effectively navigate sourcing, logistics, and manufacturing challenges with confidence.

• Choosing The Right PBMCS For Your Research And Product Development Needs

  Enhance the success of your research and cell therapy programs by sourcing PBMCs with proven functional performance and donor-specific insights.

• Ensuring Reliability And Patient Safety With XiltriX

  Protect the integrity of your therapies and ensure patient safety by investing in reliable, real-time environmental monitoring systems that proactively address operational vulnerabilities.

• Spotlight On Excell-Ence: Project Management Team

  Discover the difference a dedicated, expert project management team can make in ensuring the success and smooth execution of your cell therapy programs.

• Immunotherapy Development

  Immunotherapy is an evolving and promising cancer treatment that works by stimulating the immune system. More biologically relevant human primary cells are now the chosen starting material for immunotherapy development. Historically, scientists routinely used immortalized cell lines in the research and development of therapies as they offer an inexpensive and stable platform. However, they are not fully representative of what is going on in vivo.

• Allogeneic CAR-T Cells

  Allogeneic CAR-T Cells Vs Autologous

  Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. Clinical trials with autologous CAR-T cells have shown very promising results and led to the approval of numerous CAR-T cell therapies.

• Cell Therapy From Culture To Cure: Enabling Your Path From Discovery To Commercialization

  Realize the full potential of your cell therapy research. Experience end-to-end support to overcome developmental complexities, helping you to efficiently and safely commercialize your groundbreaking treatments.

• Linking Clinical Correlates To Cell Therapy Outcomes

  Streamline cell therapy development by transforming complex cellular characteristics into a predictive, multiparametric metric that guides the selection of high-potential starting material.